Heart Failure With Preserved Ejection Fraction and Diabetes
Open accessAbstract
Heart failure with preserved ejection fraction (HFpEF) is now the most common form of HF, affecting over 3 million adults in the United States alone. HFpEF is a heterogenous syndrome. One important phenotype may be related to comorbid conditions, including diabetes mellitus (DM). DM has a prevalence of approximately 45% in HFpEF, but characteristics and outcomes of this population are poorly understood. In this review, the authors summarize data from several clinical trials of HFpEF therapeutics and provide original data from a large cohort using the Get With The Guidelines-HF registry, which together suggest that DM is associated with increased morbidity and long-term mortality in HFpEF. The authors then discuss several common pathological mechanisms in HFpEF and DM, including sodium retention, metabolic derangements, impaired skeletal muscle function, and potential therapeutic targets. As the understanding of comorbid HFpEF and DM improves, it is hoped clinicians will be better equipped to offer effective, patient-centered treatments.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Type 2 diabetes is common in patients with HFpEF.
“Type 2 diabetes is common in patients with HFpEF. 4-6”
From Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials (2024) · cites this paper as [5]
The introductory passage labeled Abstract reports that about 45% of patients with HFpEF have diabetes mellitus, supporting that diabetes is common in this population. It does not specify that this prevalence is for type 2 diabetes. (LLM, conf=0.83)
Experimental — accuracy not yet measuredBoth morbidity and long-term mortality of HFpEF are greatly worsened by a coexisting diabetes, and this adverse outcome cannot be offset by effective treatments.
“Both morbidity and long-term mortality of HFpEF are greatly worsened by a coexisting diabetes and this adverse outcome cannot be offset by effective treatments [71,76].”
From Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes (2022) · cites this paper as [71]
HFpEF is a heterogeneous syndrome characterized by a frequent association with multiple comorbidities (mainly diabetes and obesity), a complex pathophysiology, and a variegate clinical expression with different phenotypes.
“HFpEF is a heterogeneous syndrome characterized by a frequent association with multiple comorbidities (mainly diabetes and obesity), a complex pathophysiology originating from the interplay of cardiac and extracardiac abnormalities, and a consequent variegate clinical expression with different phenotypes [71].”
From Dysregulated epicardial adipose tissue as a risk factor and potential therapeutic target of heart failure with preserved ejection fraction in diabetes (2022) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 32 · Cited by 313
Research works printed but not linked: 1
- Butler J, Hamo CE, Filippatos G, et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 in- hibitors. Eur J Heart Fail 2017;19:1390-400.
- Authors
- McHugh, K., DeVore, A. D., Wu, J., Matsouaka, R. A., Fonarow, G. C., Heidenreich, P. A., Yancy, C. W., Green, J. B., Altman, N., & Hernandez, A. F.
- Affiliations
- Duke University (US)
- Duke Clinical Research Institute (US)
- University of California, Los Angeles (US)
- VA Palo Alto Health Care System (US)
- Northwestern University (US)
- University of Colorado Anschutz (US)
- Corresponding author
- Hernandez, Adrian F.
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 73
- Issue
- 5
- Pages
- 602-611
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2911902516
- Cited by
- 313
- References
- 32
- Citations by year
- 2026: 27 · 2025: 47 · 2024: 57 · 2023: 50 · 2022: 53 · 2021: 45 · 2020: 27 · 2019: 7
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association (16SFRN30180010)
- Amgen
- Bristol-Myers Squibb
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Boston Scientific Corporation
- Regeneron Pharmaceuticals
- Intarcia Therapeutics
- Luitpold Pharmaceuticals
- Daiichi-Sankyo
- Novo Nordisk
- National Institutes of Health
- St. Jude Medical
- Daiichi Sankyo Company
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- heart failure with preserved ejection fraction, diabetes mellitus, comorbidities, mortality, morbidity, sodium retention, metabolic disorders, skeletal muscle function, therapeutic target
- MeSH terms
- Diabetes Mellitus, Heart Failure, Humans, Stroke Volume, Comorbidity, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
